WO2002024214A3 - Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders - Google Patents

Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders Download PDF

Info

Publication number
WO2002024214A3
WO2002024214A3 PCT/GB2001/004178 GB0104178W WO0224214A3 WO 2002024214 A3 WO2002024214 A3 WO 2002024214A3 GB 0104178 W GB0104178 W GB 0104178W WO 0224214 A3 WO0224214 A3 WO 0224214A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
nutrition
bone
combination
another therapeutic
Prior art date
Application number
PCT/GB2001/004178
Other languages
French (fr)
Other versions
WO2002024214A2 (en
Inventor
Dennis Bang Henriksen
Original Assignee
Osteometer Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022844A external-priority patent/GB0022844D0/en
Priority claimed from GB0029920A external-priority patent/GB0029920D0/en
Application filed by Osteometer Biotech As filed Critical Osteometer Biotech As
Priority to AU2001287892A priority Critical patent/AU2001287892A1/en
Priority to DE60142084T priority patent/DE60142084D1/en
Priority to DK01967517.2T priority patent/DK1414486T3/en
Priority to JP2002528284A priority patent/JP5189723B2/en
Priority to AT01967517T priority patent/ATE466592T1/en
Priority to EP01967517A priority patent/EP1414486B1/en
Publication of WO2002024214A2 publication Critical patent/WO2002024214A2/en
Publication of WO2002024214A3 publication Critical patent/WO2002024214A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.
PCT/GB2001/004178 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders WO2002024214A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001287892A AU2001287892A1 (en) 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
DE60142084T DE60142084D1 (en) 2000-09-18 2001-09-18 USE OF GLP-2 IN CONNECTION WITH ANOTHER THERAPEUTIC AGENT IN BONE DISEASES
DK01967517.2T DK1414486T3 (en) 2000-09-18 2001-09-18 Use of GLP-2 in combination with another therapeutic agent in bone-related diseases
JP2002528284A JP5189723B2 (en) 2000-09-18 2001-09-18 Methods of using GLP for the treatment, prevention, diagnosis and prognosis of bone and nutrition related diseases
AT01967517T ATE466592T1 (en) 2000-09-18 2001-09-18 USE OF GLP-2 IN CONJUNCTION WITH ANOTHER THERAPEUTIC AGENT IN BONE DISEASES
EP01967517A EP1414486B1 (en) 2000-09-18 2001-09-18 Use of glp-2 in combination with another therapeutic agent in bone-related disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0022844.5 2000-09-18
GB0022844A GB0022844D0 (en) 2000-09-18 2000-09-18 Use of GLP-1 and GLP-2 peptides
GB0029920.6 2000-12-07
GB0029920A GB0029920D0 (en) 2000-12-07 2000-12-07 Use of glp-1 and glp-2 peptides

Publications (2)

Publication Number Publication Date
WO2002024214A2 WO2002024214A2 (en) 2002-03-28
WO2002024214A3 true WO2002024214A3 (en) 2004-02-19

Family

ID=26245018

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2001/010714 WO2002022151A2 (en) 2000-09-18 2001-09-17 Use of glp-1 and flp-2 peptides for treatment of bone disorders
PCT/GB2001/004178 WO2002024214A2 (en) 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010714 WO2002022151A2 (en) 2000-09-18 2001-09-17 Use of glp-1 and flp-2 peptides for treatment of bone disorders

Country Status (11)

Country Link
US (2) US6770620B2 (en)
EP (3) EP1326630B1 (en)
JP (2) JP5161412B2 (en)
AT (2) ATE396738T1 (en)
AU (2) AU2002213925A1 (en)
CY (2) CY1108263T1 (en)
DE (2) DE60134251D1 (en)
DK (2) DK1326630T3 (en)
ES (2) ES2310192T3 (en)
PT (2) PT1326630E (en)
WO (2) WO2002022151A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
RO120121B1 (en) * 2000-12-18 2005-09-30 Elena Ionaşcu Injectable solution having antiinflammatory effect, process for preparing the same and method for treating autoimmune diseases
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE10135315A1 (en) * 2001-07-19 2003-01-30 Bayer Ag stents
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CA2483464C (en) * 2002-05-17 2011-12-20 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
JP2007525425A (en) * 2003-03-24 2007-09-06 ノボ　ノルディスク　アクティーゼルスカブ GLP-2 derivative
ES2303085T3 (en) * 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. COMPOSITIONS AFFECTING LOSS OF WEIGHT.
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2004103390A2 (en) 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
JP2007517901A (en) * 2004-01-13 2007-07-05 デューク・ユニバーシティー Antispasmodic and antipsychotic compositions that affect weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007536229A (en) * 2004-05-03 2007-12-13 デューク・ユニバーシティー Composition for acting on weight loss
BRPI0610091B1 (en) 2005-05-04 2021-08-03 Zealand Pharma A/S GLUCAGON TYPE PEPTIDE 2 ANALOG (GLP-2), PHARMACEUTICAL COMPOSITION, USE OF A GLP-2 ANALOG, E, THERAPEUTIC KIT
WO2006135660A2 (en) * 2005-06-10 2006-12-21 University Of Chicago Therapies involving lymphotoxin beta receptor
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20080031957A1 (en) * 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
CN101573376B (en) 2006-11-08 2013-11-06 西兰制药公司 Selective glucagon-like-peptide-2 (GLP-2) analogues
KR20190042766A (en) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
JP2010539052A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of peptides as therapeutic agents
MX2010012909A (en) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Methods for treating visceral fat conditions.
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2337585A1 (en) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101939557B1 (en) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
BR112012006437A2 (en) * 2009-09-23 2016-04-19 Biokier Inc compositions and methods for treating diabetes and other disorders
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
CN107308442B (en) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine
PT3345593T (en) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
LT2611458T (en) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20150087689A1 (en) * 2011-05-24 2015-03-26 Polyvalor, Limited Partnership COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF siRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES
TR201802689T4 (en) 2012-05-03 2018-03-21 Zealand Pharma As Glucagon-like peptide-2 (glp-2) analogs.
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
UA117480C2 (en) 2013-04-03 2018-08-10 Санофі Treatment of diabetes mellitus by long–acting formulations of insulins
CN105637363B (en) 2013-08-01 2017-06-27 庆熙大学校产学协力团 The method of prevention or the pharmaceutical composition for the treatment of diabetes, prevention or treatment diabetes, and the method for screening Remedies for diabetes
WO2015016682A1 (en) * 2013-08-01 2015-02-05 경희대학교 산학협력단 Pharmaceutical composition for preventing or treating diabetes mellitus, method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
SI3229828T1 (en) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2018009778A1 (en) * 2016-07-07 2018-01-11 Baylor College Of Medicine Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
US10774127B2 (en) 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
JP6563614B1 (en) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス Acylated GLP-1 / GLP-2 dual agonist
WO2019072963A1 (en) 2017-10-12 2019-04-18 University Of Copenhagen Combination therapy for treatment of bone disorders
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
WO2021133087A1 (en) * 2019-12-24 2021-07-01 한미약품 주식회사 Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
EP4257144A1 (en) * 2020-09-25 2023-10-11 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or conjugate thereof having activity with respect to all of glucagon, glp-1 and glp receptors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032414A1 (en) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997031943A1 (en) * 1996-03-01 1997-09-04 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
WO1998024813A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives
WO1998052600A1 (en) * 1997-05-16 1998-11-26 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110083T1 (en) 1986-05-05 1994-09-15 Gen Hospital Corp INSULINOTROPIC HORMONE.
JPH04504246A (en) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション insulin stimulating hormone
JP3262329B2 (en) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU733857B2 (en) 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
DE69717629T2 (en) 1996-07-05 2003-09-11 Novo Nordisk As METHOD FOR PRODUCING POLYPEPTIDES
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
EP0946591B1 (en) 1996-12-13 2007-04-04 Allelix Biopharmaceuticals Inc. Cloned glucagon-like peptide-2 receptors
US6077949A (en) 1996-12-13 2000-06-20 Allelix Biopharmaceuticals, Inc. Cloned glucagon-like peptide 2 receptors
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999006059A2 (en) 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
WO1999037793A1 (en) 1998-01-23 1999-07-29 Novo Nordisk A/S Process for making desired polypeptides in yeast
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
WO1999043361A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
FR2777283B1 (en) * 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO1999058144A1 (en) 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
AU5480199A (en) 1998-08-21 2000-03-14 Point Therapeutics, Inc. Regulation of substrate activity
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US7368427B1 (en) * 1998-12-07 2008-05-06 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas GLP-1 analogues
US6903186B1 (en) * 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
JP2002534512A (en) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ Non-peptide GLP-1 agonist
GB9905416D0 (en) 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
ATE424413T1 (en) * 2000-06-16 2009-03-15 Lilly Co Eli ANALOGUE OF GLUCAGONE-LIKE PEPTIDE-1
BR0113178A (en) * 2000-08-02 2004-04-06 Theratechnologies Inc Modified biological peptides with increased potency
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032414A1 (en) * 1995-04-14 1996-10-17 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997031943A1 (en) * 1996-03-01 1997-09-04 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
WO1998024813A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives
WO1998052600A1 (en) * 1997-05-16 1998-11-26 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCIS R.M.: "Biphosphonates in the treatment of osteoporosis in 1997: a review", CURRENT THERAPEUTIC RESEARCH, vol. 58, no. 10, October 1997 (1997-10-01), pages 656 - 678, XP002220205 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
US20020037836A1 (en) 2002-03-28
WO2002024214A2 (en) 2002-03-28
JP2004508410A (en) 2004-03-18
EP1326630A2 (en) 2003-07-16
US6943151B2 (en) 2005-09-13
CY1108263T1 (en) 2014-02-12
EP1970072A1 (en) 2008-09-17
CY1110721T1 (en) 2015-06-10
JP2004524268A (en) 2004-08-12
DK1414486T3 (en) 2010-08-30
EP1414486A2 (en) 2004-05-06
WO2002022151A2 (en) 2002-03-21
EP1326630B1 (en) 2008-05-28
ATE396738T1 (en) 2008-06-15
US6770620B2 (en) 2004-08-03
DE60134251D1 (en) 2008-07-10
DE60142084D1 (en) 2010-06-17
PT1326630E (en) 2008-09-02
ES2310192T3 (en) 2009-01-01
AU2002213925A1 (en) 2002-03-26
AU2001287892A1 (en) 2002-04-02
DK1326630T3 (en) 2008-09-15
WO2002022151A3 (en) 2003-03-13
JP5189723B2 (en) 2013-04-24
ES2345874T3 (en) 2010-10-05
PT1414486E (en) 2010-07-21
US20040082507A1 (en) 2004-04-29
JP5161412B2 (en) 2013-03-13
ATE466592T1 (en) 2010-05-15
EP1414486B1 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
WO2002024214A3 (en) Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU2001236798A1 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU2459402A (en) Composition
IL151128A0 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
WO1998030242A3 (en) Photochemotherapeutic compositions
HK1089376A1 (en) Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
PL376894A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
EP1406648A4 (en) The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
PL376895A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
AU2003278664A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
GB2370507B (en) Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders
EP1330251A4 (en) Combination therapy for the treatment of estrogen-sensitive disease
EP1371371A4 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
EP1440163A4 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
EP1440169A4 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 57749
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
EP1439862A4 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
AU2000230653A1 (en) Diagnosis and treatment of mental disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002528284

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001967517

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001967517

Country of ref document: EP